No abstract available
Publication types
-
Clinical Trial
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage*
-
Adult
-
Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
-
Aryl Hydrocarbon Hydroxylases / genetics*
-
Aryl Hydrocarbon Hydroxylases / metabolism
-
Clopidogrel
-
Cytochrome P-450 CYP2C19
-
Dose-Response Relationship, Drug
-
Drug Interactions
-
Heterozygote
-
Homozygote
-
Humans
-
Lansoprazole
-
Male
-
Phenotype
-
Platelet Aggregation / drug effects*
-
Platelet Aggregation Inhibitors / administration & dosage*
-
Platelet Aggregation Inhibitors / metabolism
-
Polymorphism, Genetic*
-
Proton Pump Inhibitors / administration & dosage*
-
Ticlopidine / administration & dosage
-
Ticlopidine / analogs & derivatives*
-
Ticlopidine / metabolism
-
Young Adult
Substances
-
2-Pyridinylmethylsulfinylbenzimidazoles
-
Platelet Aggregation Inhibitors
-
Proton Pump Inhibitors
-
Lansoprazole
-
Clopidogrel
-
Aryl Hydrocarbon Hydroxylases
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Ticlopidine